Figure 1.

Per‐unit infectious risk for HBV, HCV, and HIV from 1980 to 2018 and emerging infectious agents that were investigated for potential TT over the past 25 years. Agents proven to be blood safety threats for which interventions were implemented are in red, agents that were established to be legitimate infectious agents but not TT or associated with diseases are in blue, and alleged threats that were determined to not cause human infections or due to artifacts are shown in green. No interventions for HEV have yet been implemented in the United States, but interventions have been implemented in some countries where HEV incidence is higher. ICL = idiopathic CD4+ T‐lymphocytopenia; HGV = hepatitis G virus; SFV = simian foamy virus; PTLV = primate T‐cell lymphotrophic viruses; SARS = severe acute respiratory syndrome; PARV‐4 = parvovirus type 4; SFTSV = severe fever with thrombocytopenia virus; MERS‐CoV = Middle Eastern respiratory syndrome coronavirus; Ab = antibody; Ag = antigen; HBsAg = hepatitis B surface antigen; vCJD = variant Creutzfeldt‐Jakob disease. This figure was updated from Perkins and Busch.1 [Color figure can be viewed at http://wileyonlinelibrary.com]